NASHVILLE, Tenn., Sept. 24, 2018 /PRNewswire/ -- Cumberland
Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to announced
that Joe Galante, music industry
executive, has joined its Board of Directors. He is the former
Chairman of Sony Music in Nashville and President of RCA Records in
New York City. Mr. Galante is also
currently a member of the Board of Directors of Pinnacle Financial
Partners, whose shares are listed on the NASDAQ stock exchange, as
well as the Country Music Association and the chair of CMA
Foundation.
Mr. Galante is recognized as a music industry leader, having
played a key role in developing the careers of some of the top
music artists in the world, including Alabama, Dave
Mathews band, Carrie
Underwood, Kenny Chesney,
Brad Paisley, Martina McBride, Miranda
Lambert, Dolly Parton and the
Judds, among others.
He began his career at RCA Records in New York, followed by a transfer to RCA
Nashville where he served as a director at the label, followed by
the role of Vice President Promotion and Marketing. At the age of
32, he became the youngest person ever named to run a major country
music record label. In 1990 he was named the President of RCA
Records in New York. He returned
to Nashville as Chairman to run
the RCA and BNA labels there. Under his leadership, RCA Records was
the number one country label for 11 consecutive years. He then
served as Chairman of Sony Music Nashville for six years. He was
presented with the Bob Kingsley Living Legend Award by the Opry
Trust to honor his work in country music.
"We are delighted to welcome Joe
Galante to our Board of Directors. His successful business
track record, entrepreneurial and public company experience make
him a valuable new member of our Board," said A.J. Kazimi, Chief
Executive Officer of Cumberland Pharmaceuticals. "We are fortunate
to be headquartered in Nashville,
one of the country's most successful cities in the 21st
century. Our two largest industries here are healthcare and
entertainment, and we now have leaders of both those industries
helping to build our company through their participation on our
Board."
Mr. Galante's appointment to Cumberland's Board as an independent director
is effective September 19, 2018.
Cumberland's Board of Directors
also includes Joey Jacobs, Chairman
and CEO of Acadia Healthcare, Dr. Gordon
Bernard, Associate Vice-Chancellor for Research at
Vanderbilt University Medical Center,
Jamie Jones, former Managing Partner
of KPMG LLP's Middle Tennessee operations, Jon Griggs, Former Vice President Human
Resources at Warner-Lambert Company, Caroline Young, former President of the
Nashville Healthcare Council and current President of Nashville
Health, and Ken Krogulski, President
and Chief Executive Officer of Berkshire Asset Management LLC, who
also all serve as independent directors.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical
company focused on the delivery of high-quality prescription brands
to improve patient care. The Company develops, acquires, and
commercializes brands for the hospital acute care,
gastroenterology, and oncology market segments. These medical
specialties are categorized by moderately concentrated prescriber
bases that we believe can be penetrated effectively by small,
targeted sales forces.
The Company's portfolio of FDA approved brands includes:
- Acetadote® (acetylcysteine) Injection,
for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) Injection, for
the treatment of pain and fever;
- Kristalose® (lactulose) for Oral
Solution, a prescription laxative, for the treatment of chronic and
acute constipation;
- Omeclamox®-Pak, (omeprazole,
clarithromycin, amoxicillin) for the treatment of Helicobacter
pylori (H. pylori) infection and related duodenal ulcer
disease;
- Vaprisol® (conivaptan) Injection, to
raise serum sodium levels in hospitalized patients with euvolemic
and hypervolemic hyponatremia;
- Ethyol® (amifostine) Injection, for
the reduction of xerostomia (dry mouth) in patients undergoing
post-operative radiation treatment for head and neck cancer and the
renal toxicity associated with the administration of cisplatin in
patients with advanced ovarian cancer;
- Totect® (dexrazoxane hydrochloride)
Injection, for emergency oncology intervention, to treat the toxic
effects of anthracycline chemotherapy in case of extravasation
(drug leakage from the bloodstream into the tissues).
Cumberland's pipeline of
product candidates includes:
- RediTrex™ (methotrexate) Injection, an
approval submission candidate for the treatment of active
rheumatoid, juvenile idiopathic and severe psoriatic
arthritis;
- Hepatoren® (ifetroban) Injection, a
Phase II candidate for the treatment of critically ill patients
suffering from liver and kidney failure associated with hepatorenal
syndrome ("HRS");
- Boxaban® (ifetroban) Oral Capsules, a
Phase II candidate for the treatment of asthma patients with
aspirin-exacerbated respiratory disease ("AERD");
- Vasculan® (ifetroban) Oral Capsules, a
Phase II candidate for the treatment of patients with the systemic
sclerosis (SSc) form of autoimmune disease;
- Portaban® (ifetroban) Injection
and Oral Capsules, a Phase II candidate for the treatment of
patients with portal hypertension associated with liver
disease.
For more information on Cumberland's products, including full
prescribing information, please visit the individual product
websites, which can be found on the Company's website
www.cumberlandpharma.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-senior-music-industry-executive-joins-its-board-of-directors-300717343.html
SOURCE Cumberland Pharmaceuticals Inc.